Table 1.
Patient characteristics.
| Characteristic | n = 105 (100%) |
|---|---|
| Gender | |
| Data available | 41 (40%) |
| Men | 17 (41.5%) |
| Women | 24 (58.5%) |
| NA | 64 (61.0%) |
| Median age | 44 years (18–73) |
| Functioning NEN | |
| Data available | 83 (79%) |
| Yes | 31 (37.3%) |
| No | 52 (62.7%) |
| NA | 22 (21%) |
| Type of syndrome in functioning NEN | |
| Data available | 29 (27.6%) |
| Gastrinoma | 19 (65.6%) |
| Glucagonoma | 6 (20.7%) |
| Insulinoma | 2 (6.9%) |
| Somatostatinoma | 1 (3.4%) |
| Gastrinoma + insulinoma | 1 (3.4%) |
| NA | 76 (72.4%) |
| Stage | |
| Data available | 92 (87.6%) |
| I | 73 (79.3%) |
| II | 5 (5.4%) |
| III | 0 (0.0%) |
| IV | 14 (15.2%) |
| NA | 13 (12.4%) |
| Number of pancreatic nodules | |
| Data available | 64 (60.9%) |
| 1 | 25 (39.1%) |
| >1 | 39 (60.9%) |
| NA | 41 (39.0%) |
| Grade | |
| Data available | 29 (27.6%) |
| 1 | 10 (34.5%) |
| 2 | 19 (65.5%) |
| NA | 76 (72.4%) |
| Median Ki67 index (%) | |
| 2 (1–8) | |
| MEN1 manifestations | |
| Data available | 33 (31.5%) |
| Hyperparathyroidism | 15 (45.5%) |
| Pituitary adenoma | 1 (3.0%) |
| Hyperparathyroidism and pituitary adenoma | 17 (51.5%) |
| NA | 72 (68.6%) |
| Surgery | |
| Data available | 54 (51.4%) |
| Yes | 23 (42.6%) |
| No | 31 (57.4%) |
| NA | 51 (48.6%) |
| Short-acting SSA therapy | |
| Yes | 24 (22.9%) |
| No | 81 (77.1%) |
| Octreotide LAR | |
| Yes | 73 (69.5%) |
| No | 32 (30.5%) |
| Lanreotide LAR | |
| Yes | 28 (26.7%) |
| No | 77 (73.3%) |
| Response to SSA therapy | |
| Data available | 78 (74.2%) |
| SD | 59 (75.6%) |
| PR | 7 (9.0%) |
| CR | 3 (3.8%) |
| PD | 9 (11.5%) |
| NA | 27 (25.7%) |
| Side effects to SSA therapy | |
| No | 95 (90.4%) |
| Gallstones | 6 (5.7%) |
| Hyperglycaemia | 2 (1.9%) |
| Gastrointestinal (nausea, diarrhea) | 1 (0.9%) |
| Pain | 1 (0.9%) |
Abbreviations: NA = not available.